Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$8.63 - $15.52 $10,364 - $18,639
-1,201 Reduced 2.96%
39,357 $349,000
Q2 2022

Aug 11, 2022

SELL
$8.59 - $20.77 $31,585 - $76,371
-3,677 Reduced 8.31%
40,558 $513,000
Q1 2022

May 11, 2022

BUY
$15.52 - $35.65 $50,828 - $116,753
3,275 Added 8.0%
44,235 $837,000
Q4 2021

Feb 10, 2022

SELL
$28.89 - $35.33 $302,420 - $369,834
-10,468 Reduced 20.35%
40,960 $1.44 Million
Q3 2021

Nov 12, 2021

BUY
$35.66 - $42.94 $177,943 - $214,270
4,990 Added 10.75%
51,428 $1.88 Million
Q2 2021

Aug 12, 2021

SELL
$23.7 - $39.27 $38,749 - $64,206
-1,635 Reduced 3.4%
46,438 $1.82 Million
Q1 2021

May 14, 2021

BUY
$27.01 - $36.8 $386,297 - $526,313
14,302 Added 42.35%
48,073 $1.36 Million
Q4 2020

Feb 11, 2021

BUY
$27.51 - $34.36 $65,858 - $82,257
2,394 Added 7.63%
33,771 $1.08 Million
Q3 2020

Nov 13, 2020

BUY
$25.8 - $34.61 $305,317 - $409,574
11,834 Added 60.55%
31,377 $1.01 Million
Q2 2020

Aug 10, 2020

BUY
$17.65 - $28.05 $143,017 - $227,289
8,103 Added 70.83%
19,543 $539,000
Q1 2020

May 12, 2020

BUY
$15.19 - $29.51 $41,423 - $80,473
2,727 Added 31.3%
11,440 $204,000
Q4 2019

Feb 10, 2020

BUY
$17.17 - $25.95 $32,537 - $49,175
1,895 Added 27.79%
8,713 $218,000
Q3 2019

Nov 12, 2019

SELL
$17.84 - $22.69 $38,784 - $49,328
-2,174 Reduced 24.18%
6,818 $122,000
Q2 2019

Aug 13, 2019

SELL
$22.0 - $31.78 $207,284 - $299,431
-9,422 Reduced 51.17%
8,992 $198,000
Q1 2019

May 06, 2019

BUY
$21.27 - $30.58 $23,588 - $33,913
1,109 Added 6.41%
18,414 $0
Q4 2018

Feb 14, 2019

BUY
$23.09 - $37.69 $399,572 - $652,225
17,305 New
17,305 $400,000

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Krane Funds Advisors LLC Portfolio

Follow Krane Funds Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Krane Funds Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Krane Funds Advisors LLC with notifications on news.